New Patented Medicines Reported to PMPRB

Up to date as of September 12, 2018

Search by:

to

* Note: Drugs with Price Review Records linked from the brand name are only available from 2010 onward (records for 2011 will be populated over the next few months). Summary Reports are available for drug products reported prior to 2010.


YearCompanyBrand NameChemical NameDINTherapeutic UseDate of First SaleStatus
2017AbbvieMaviret 100/40 - 140 mg/tabletglecaprevir/pibrentasvir02467550Hepatitis C13 Sep 2017Within Guidelines
2017Allergan Inc.Viberzi - 75 mg/tableteluxadoline02460890Irritable bowel syndrome24 Apr 2017Within Guidelines
2017Allergan Inc.Viberzi - 100 mg/tableteluxadoline02460904Irritable bowel syndrome24 Apr 2017Within Guidelines
2017Amgen Canada Inc.Repatha - 120 mg/mLevolocumab02459779Cholesterol4 Apr 2017VCU
2017Amgen Canada Inc.Kyprolis - 10 mg/vialcarfilzomib02459930Cancer13 Feb 2017Within Guidelines
2017Amgen Canada Inc.Kyprolis - 30 mg/vialcarfilzomib02459949Cancer6 Feb 2017Within Guidelines
2017Amgen Canada Inc.Vectibix - 20 mg/mLpanitumumab02308509Cancer3 Jan 2017VCU
2017Baxalta Canada CorporationRixubis - 500 unit/vialRecombinant Coagulation Factor IX (rFIX), NONACOG GAMMA02431939Hemophilia6 Apr 2017Within Guidelines
2017Baxalta Canada CorporationRixubis - 1000 unit/vialRecombinant Coagulation Factor IX (rFIX), NONACOG GAMMA02431947Hemophilia6 Apr 2017Does Not Trigger Investigation
2017Baxalta Canada CorporationRixubis - 2000 unit/vialRecombinant Coagulation Factor IX (rFIX), NONACOG GAMMA02431955Hemophilia6 Apr 2017Does Not Trigger Investigation
2017Biogen Canada Inc.Zinbryta - 150 mg/mLdaclixumab beta02459620Multiple sclerosis30 Mar 2017Within Guidelines
2017Boehringer Ingelheim (Canada) Ltd.Glyxambi 10/5 - 15 mg/tabletempagliflozin/linagliptin02459752Diabetes19 Dec 2016Within Guidelines
2017Boehringer Ingelheim (Canada) Ltd.Glyxambi 25/5 - 30 mg/tabletempagliflozin/linagliptin02459760Diabetes19 Dec 2016Within Guidelines
2017BTG International Ltd.Varithena - 1.3 mg/mLpolidocancol02444267Venous reflux10 Mar 2017Within Guidelines
2017Celgene Inc.Revlimid - 2.5 mg/capsulelenalidomide02459418Anemia20 Dec 2016Within Guidelines
2017Duchesnay Inc.Mictoryl - 30 mg/capsulepropiverine hydrochloride02460262Incontinence8 May 2017Within Guidelines
2017Duchesnay Inc.Mictoryl - 45 mg/capsulepropiverine hydrochloride02460270Incontinence8 May 2017Within Guidelines
2017Duchesnay Inc.Mictoryl Pediatric - 5 mg/tabletpropiverine hydrochloride02460289Incontinence17 Apr 2017Does Not Trigger Investigation
2017EMD Serono Canada Inc.Mavenclad - 10 mg/tabletcladribine02470179Multiple sclerosis30 Nov 2017Within Guidelines
2017Gilead Sciences Canada Inc.Vosevi 400/100/100 - 600 mg/tabletsofosbuvir/velpatasvir/voxilaprevir02467542Hepatitis C18 Sep 2017Within Guidelines
2017Gilead Sciences Canada Inc.Odefsey 200/25/25 - 250 mg/tabletemtricitabine/rilpivirine/tenofovir alafenamide02461463HIV20 Mar 2017Within Guidelines
2017Gilead Sciences Canada Inc.Vemlidy - 25 mg/tablettenofovir alafenamide02464241Hepatitis B20 Jun 2017Within Guidelines
2017Hoffmann-La Roche LimitedEsbriet - 267 mg/tabletpirfenidone02464489Idiopathic Pulmonary Fibrosis26 Jul 2017Within Guidelines
2017Hoffmann-La Roche LimitedEsbriet - 801 mg/tabletpirfenidone02464500Idiopathic Pulmonary Fibrosis26 Jul 2017Within Guidelines
2017Hoffmann-La Roche LimitedOcrevus - 30 mg/mLocrelizumab02467224Multiple sclerosis21 Sep 2017Within Guidelines
2017Hoffmann-La Roche LimitedTecentriq - 60 mg/mLatezolizumab02462990Cancer2 May 2017Within Guidelines
2017Horizon Pharma PLCProcysbi - 25 mg/capsulecysteamine bitartrate02464705Nephropathic cystinosis7 Sep 2017Subject to Investigation
2017Horizon Pharma PLCProcysbi - 75 mg/capsulecysteamine bitartrate02464713Nephropathic cystinosis7 Sep 2017Subject to Investigation
2017Horizon Pharma PLCQuinsair - 100 mg/mLlevofloxacine02442302Cystic fibrosis12 Dec 2016VCU
2017Intercept Pharmaceuticals Inc.Ocaliva - 5 mg/tabletobeticholic acid02463121Primary biliary cholangitis25 May 2017Within Guidelines
2017Intercept Pharmaceuticals Inc.Ocaliva - 10 mg/tabletobeticholic acid02463148Primary biliary cholangitis25 May 2017Within Guidelines
2017Ipsen Biopharmaceuticals Canada Inc.Dysport Therapeutic - 300 unit/vialabobotulinumtoxinA02460203Spasticity28 Feb 2017Within Guidelines
2017Ipsen Biopharmaceuticals Canada Inc.Dysport Therapeutic - 500 unit/vialabobotulinumtoxinA02456117Spasticity28 Feb 2017Within Guidelines
2017Janssen Inc.Stelara - 130 mg/vialustekinumab02459671Psoriasis3 Jan 2017Within Guidelines
2017Janssen Inc.Tremfya - 100 mg/mLguselkumab02469758Psoriasis28 Nov 2017Within Guidelines
2017Medexus Inc.Metoject Subcutaneous - 17.5 mg/syringemethotrexate sodium02454769Neoplastic diseases21 Dec 2016VCU
2017Medexus Inc.Metoject Subcutaneous - 22.5 mg/syringemethotrexate sodium02454777Neoplastic diseases21 Dec 2016VCU
2017Medexus Inc.Metoject Subcutaneous - 20 mg/syringemethotrexate sodium02454866Neoplastic diseases21 Dec 2016VCU
2017Medexus Inc.Metoject Subcutaneous - 25 mg/syringemethotrexate sodium02454874Neoplastic diseases14 Dec 2016VCU
2017Merck Canada Inc.Isentress HD - 600 mg/tabletraltegravir potassium02465337HIV11 Sep 2017Subject to Investigation
2017Merck Canada Inc.Keytruda - 100 mg/mLpembrolizumab02456869Cancer13 Jul 2017Within Guidelines
2017Novartis Pharmaceuticals Canada Inc.Ilaris - 150 mg/mLcanakinumab02460351Periodic Fever Syndromes22 Aug 2017Within Guidelines
2017Novartis Pharmaceuticals Canada Inc.Rydapt - 25 mg/capsulemidostaurin02466236Cancer8 Sep 2017Within Guidelines
2017Novartis Pharmaceuticals Canada Inc.Xolair - 75 mg/syringeomalizumab02459787Asthma28 Jun 2017Within Guidelines
2017Novartis Pharmaceuticals Canada Inc.Xolair - 150 mg/syringeomalizumab02459795Asthma6 Jul 2017Within Guidelines
2017Novartis Pharmaceuticals Canada Inc.Izba - 0.03 mg/mLtravoprost02457997Glaucoma6 Feb 2017Within Guidelines
2017Novo Nordisk Canada Inc.Fiasp - 100 unit/mLinsulin aspart02460408Diabetes6 Mar 2017Within Guidelines
2017Novo Nordisk Canada Inc.Fiasp Penfill - 100 unit/mLinsulin aspart02460416Diabetes6 Mar 2017Within Guidelines
2017Novo Nordisk Canada Inc.Fiasp FlexTouch - 100 unit/mLinsulin aspart02460424Diabetes6 Mar 2017Within Guidelines
2017Otsuka Canada Pharmaceutical Inc.Rexulti - 0.25 mg/tabletbrexpiprazole02461749Schizophrenia19 Apr 2017Within Guidelines
2017Otsuka Canada Pharmaceutical Inc.Rexulti - 0.5 mg/tabletbrexpiprazole02461757Schizophrenia19 Apr 2017Within Guidelines
2017Otsuka Canada Pharmaceutical Inc.Rexulti - 1 mg/tabletbrexpiprazole02461765Schizophrenia19 Apr 2017Within Guidelines
2017Otsuka Canada Pharmaceutical Inc.Rexulti - 2 mg/tabletbrexpiprazole02461773Schizophrenia19 Apr 2017Within Guidelines
2017Otsuka Canada Pharmaceutical Inc.Rexulti - 3 mg/tabletbrexpiprazole02461781Schizophrenia19 Apr 2017Within Guidelines
2017Otsuka Canada Pharmaceutical Inc.Rexulti - 4 mg/tabletbrexpiprazole02461803Schizophrenia19 Apr 2017Within Guidelines
2017Paladin Labs Inc.Movapo - 10 mg/mLapomorphine hydrochloride02459132Parkinson's Disease7 Sep 2017Within Guidelines
2017Paladin Labs Inc.Silenor - 3 mg/tabletdoxepin02398257Insomnia8 Jan 2013 (Patented 31 Jan 2017)Within Guidelines
2017Paladin Labs Inc.Silenor - 6 mg/tabletdoxepin02398265Insomnia8 Jan 2013 (Patented 31 Jan 2017)Within Guidelines
2017Pediapharm Inc.Otixal 3/0.25 - 3.25 mg/mLciprofloxacin/flucinolone acetonide02459655Acute otitis media8 May 2017Subject to Investigation
2017Pierre Fabre Dermo - Cosmétique Canada Inc.Hemangiol - 3.75 mg/mLpropranolol hydrochloride02457857Hemangioma30 May 2017Within Guidelines
2017PTC Therapeutics International LimitedTranslarna - 125 mg/pouchatalurenDuchenne muscular dystrophy9 May 2017Within Guidelines
2017Purdue PharmaAkynzeo - 300.5 mg/capsulenetupitant/palonosetron02468735Nausea and vomiting20 Nov 2017Within Guidelines
2017Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.Cerdelga - 84 mg/capsuleeliglustat tartrate02463261Gaucher disease26 Jul 2017Subject to Investigation
2017Sanofi-Aventis Canada Inc.Leukine - 250 mcg/vialsargramostimHematopoietic agent4 Jan 2017Subject to Investigation
2017Sanofi-Aventis Canada Inc.Adlyxine - 0.05 mg/mLlixisenatide02464276Diabetes12 Sep 2017Within Guidelines
2017Sanofi-Aventis Canada Inc.Adlyxine - 0.1 mg/mLlixisenatide02464284Diabetes12 Sep 2017Within Guidelines
2017Sanofi-Aventis Canada Inc.Adlyxine - 1 N.A./kitlixisenatide02464349Diabetes12 Sep 2017Within Guidelines
2017Sanofi-Aventis Canada Inc.Kevzara - 150 mg/syringesarilumab02460521Rheumatoid arthritis29 Mar 2017Within Guidelines
2017Sanofi-Aventis Canada Inc.Kevzara - 200 mg/syringesarilumab02460548Rheumatoid arthritis8 Feb 2017Within Guidelines
2017Servier Canada Inc.Lixiana - 15 mg/tabletedoxaban02458640Anticoagulant25 Apr 2017Within Guidelines
2017Servier Canada Inc.Lixiana - 30 mg/tabletedoxaban02458659Anticoagulant25 Apr 2017Within Guidelines
2017Servier Canada Inc.Lixiana - 60 mg/tabletedoxaban02458667Anticoagulant25 Apr 2017Within Guidelines
2017Shire Canada Inc.Vyvanse - 70 mg/capsulelisdexamfetamine dimesylate02458071ADHD4 Jan 2017Within Guidelines
2017Shire Canada Inc.Onivyde - 4.3 mg/mLirinotecan hydrochloride trihydrate02467135Cancer10 Oct 2017Subject to Investigation
2017Tribute Pharmaceuticals Canada LtdBlexten - 20 mg/tabletbilastine02454130Rhinitis2 Dec 2016Within Guidelines
2017UCB Canada Inc.Cimzia - 200 mg/mLcertolizumab pegol02465574Rheumatoid arthritis19 Sep 2017Subject to Investigation
2017Valeant Canada LPBepreve - 15 mg/mLbepotastine besilate02456532Conjunctivitis23 Mar 2017Within Guidelines
2017Vertex Pharmaceuticals Canada Inc.Orkambi 125/100 - 225 mg/tabletlumacaftor/ivacaftor02463040Cystic fibrosis20 Apr 2017Under Review
2017ViiV Healthcare ULCTivicay - 10 mg/tabletdolutegravir02461218HIV15 Jun 2017Within Guidelines
2017ViiV Healthcare ULCTivicay - 25 mg/tabletdolutegravir02461226HIV15 Jun 2017Within Guidelines